Policy / Pricing FDA accelerated approval path needs improvement, says ICER PharmaphorumThe FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.Policy / PricingRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER. Policy / PricingRead full story Post navigation Previous: Lilly says Foundayo safety confirmed in ACHIEVE-4 trialNext: Obesity’s explosive growth continues as Q1 deals exceed total 2025 value Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026